

**Invitae's mission** is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people.

**Driving down the cost of genetic information will increase its personal and clinical utility**


**Healthcare professionals are fundamental in ordering and interpreting genetic information**

**People should own and control their own genetic information**

**Genetic information is more valuable when shared**



# Enhancing the Experience for Referring Clinicians



Board-certified genetic counselors, laboratory geneticists, and clinical geneticists are available to discuss testing needs, test results, and research collaborations.

**Flexible ordering** - Clinicians can order single genes, small panels, or large panels in any combination suited to patients' diagnostic needs.

**Re-requisition** - After receiving a negative result, clinicians can request results from additional genes related to the presenting phenotype within 90 days.

**Family variant testing** - Requested variant testing of likely pathogenic and pathogenic variants available for all blood relatives of a proband with panel results obtained from Invitae.





# Adult Epilepsy

Received: 12 December 2018 | Revised: 28 May 2019 | Accepted: 7 June 2019  
DOI: 10.1111/epi.16273

FULL-LENGTH ORIGINAL RESEARCH

Epilepsia®

## Clinical utility of multigene panel testing in adults with epilepsy and intellectual disability

Felipe Borlot<sup>1,2</sup>  | Bruno Ivo de Almeida<sup>1,3</sup> | Shari L. Combe<sup>1</sup> |  
Danielle M. Andrade<sup>2,4,5</sup> | Francis M. Filloux<sup>1</sup> | Kenneth A. Myers<sup>6,7</sup> 



Received: 11 March 2019 | Revised: 19 May 2019 | Accepted: 31 May 2019  
DOI: 10.1002/epi.4.12348

FULL-LENGTH ORIGINAL RESEARCH

Epilepsia Open®

 Open Access

## Possible precision medicine implications from genetic testing using combined detection of sequence and intragenic copy number variants in a large cohort with childhood epilepsy

Rebecca Truty<sup>1</sup> | Nila Patil<sup>2</sup> | Raman Sankar<sup>2</sup> | Joseph Sullivan<sup>3</sup> | John Millichap<sup>4</sup>  |  
Gemma Carvill<sup>5</sup> | Ali Entezam<sup>1</sup> | Edward D. Esplin<sup>1</sup> | Amy Fuller<sup>1</sup> | Michelle Hogue<sup>1</sup> |  
Britt Johnson<sup>1</sup> | Amirah Khouzam<sup>1</sup> | Yuya Kobayashi<sup>1</sup> | Rachel Lewis<sup>1</sup> |  
Keith Nykamp<sup>1</sup> | Darlene Riethmaier<sup>1</sup> | Jody Westbrook<sup>1</sup> | Michelle Zeman<sup>1</sup> |  
Robert L. Nussbaum<sup>1,6</sup> | Swaroop Aradhya<sup>1</sup> 



## 1. Adults with epilepsy and intellectual disability

- PMID 31273778: Epilepsy panel testing identified an etiology in 22% of adults with epilepsy and intellectual disability.

## 2. Adults with poorly controlled seizures

- PMID 31440721: Precision medicine implications (PMIs) were immediately relevant to >33% of individuals with a positive molecular diagnosis (PosMD). Of those with PosMDs specifically related to PMIs, 66% were in children younger than 5 years, 27% in children aged 5-17 years, and the remaining 7% in adults.


## 3. Adults who are seeking out information regarding recurrence risk -- informed about their chances to pass down a susceptibility to seizures/epilepsy to their children

## 4. Adults with epilepsy "plus" clinical presentation (e.g., epilepsy + intellectual disability, autism spectrum disorder, syndromic presentation, etc.)

# Categories of Precision Medicine Implications

- Nearly **half of positive molecular diagnoses with precision medicine implications were related to contraindications** for antiepileptic drugs, largely due to variants in SCN1A.
- **10% of molecular diagnoses were related to biochemical disorders** with available treatments.
- 40% of molecular diagnoses invoked indications for specific anti-epileptic drugs (e.g. Vigabatrin for spasms in TSC).
- Another **21% of individuals** had positive molecular diagnoses in **genes with emerging association** with precision medicine implications.

**A** PosMD with PMI



# Family Variant Testing


When a patient tests positive through one of Invitae's diagnostic panel tests, family variant testing is available at no additional charge to eligible family members.

**FVT policy temporarily extended from 90 days to 150 days**

An example of our commitment to lowering barriers to genetic testing.

## Genetic insights are a family affair

- Identifying the presence of a variant can sometimes enable medical management
- Identifying the absence of a variant can also have significant implications for relatives.



# Leveraging Telehealth Capabilities

**In the clinic or at home, we're here to help.**

Our genetic testing services are supported with telehealth options.

Most Invitae genetic tests can be completed with a saliva sample kit shipped directly to your patient.



Our family variant testing and re-requisition policies have been extended to 150 days from 90 days during this time.

## Perspectives in Genetics



*"Seeing patients from home (and staying HIPAA-compliant): A guide for GCs"*



# No Surprises. Simple Billing.

Invitae is proud to be in-network for more than 300 million patients in the US - and growing.

We also offer a generous patient assistance program - click [here](#).

Only approximately 1% of genetic tests received at Invitae are cancelled due to financial concerns.

## Transparent pricing, ethical billing



**\$100**  
OUT OF POCKET

Typically patients pay no more than  
\$100 out of pocket for one of our tests



**\$250**  
PATIENT PAY

If preferred, patients have the option  
to pay \$250 per clinical area

\*After billing insurance, the majority of patients pay \$100 or less, but that amount could be higher or lower depending on the plan.

Want more details about billing at Invitae?  
Click [here](#).



INVITAE

© 2020 Invitae Corporation. All Rights Reserved. | DO NOT DISTRIBUTE